Dr. Collazo on New Long-Acting PrEP Injections in Puerto Rico
“The great majority of our patients use oral tablets, but currently we have injectable medications, both intramuscular and subcutaneous, that help us prevent HIV,” said Dr. Ronald Collazo Pagán, internal medicine physician and president of the HIV Treatment Association of Puerto Rico, Medicina y Salud Pública reported.
HIV prevention in Puerto Rico is undergoing a clinical shift as long-acting injectable pre-exposure prophylaxis alternatives emerge alongside traditional daily oral tablets, according to Medicina y Salud Pública. These new formulations aim to remove the daily dosing burden and improve preventative adherence across the population.
Key Clinical Takeaways:
- Long-acting injectable PrEP options now include a two-month intramuscular gluteal injection and a six-month subcutaneous abdominal injection.
- Clinical research is currently evaluating extended four-month intramuscular intervals, yearly injections, and a once-monthly oral pill in Phase III trials.
- Administrative barriers, such as requirements for primary care physician counter-signatures under the Government Health Plan, continue to limit timely access on the island.
Patients currently have access to an intramuscular medication administered in the gluteal area every two months, alongside a subcutaneous option applied in the abdominal tissue around the navel that provides protection for six months, Collazo Pagán told Medicina y Salud Pública. Daily oral PrEP presents adherence challenges because missed doses directly compromise drug efficacy, a hurdle that long-acting formulations address.
Collazo Pagán said that studies are evaluating the extension of intramuscular applications from every two months to every four months, alongside the development of a yearly intramuscular administration.
Phase III clinical trials are also underway for a once-monthly oral PrEP pill. Regarding the safety profile of current injectables, side effects are typically local and transient, consisting of mild pain, induration, or small nodules at the injection site due to the gradual release of the active pharmaceutical ingredient.
Sexually active individuals with multiple partners or unknown partner serostatus should consult a primary care physician or specialized clinic to evaluate starting PrEP. However, Collazo Pagán warned that educational and bureaucratic hurdles continue to restrict timely access in Puerto Rico.
“Currently, some patients who are beneficiaries of the Puerto Rico Government health plan, known as the Reform, when they go to a specialized clinic like mine, need to obtain a counter-signature from their primary care physician to be able to access PrEP,” Collazo Pagán told Medicina y Salud Pública. “Obviously, this represents an extremely large obstacle that we have to work to try to eliminate.”
Clinical practice on the island also incorporates comprehensive management for aging populations living with HIV, addressing comorbidities such as diabetes, hypertension, and neurocognitive disorders to support long-term health.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.